What are tumour agnostic cancer treatments and which biomarkers do they target? Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast. As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others. Listen to deepen your understanding of: Biomarker targets associated with tumour agnostic therapies Which tumours carry these gene alterations Appropriate genetic testing strategies to detect these biomarkers Prefer to watch as well as listen? Watch a video of the experts in conversation and get the clinical takeaways and podcast transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/tumour-agnostic-therapies/ Or go to the video on YouTube: https://www.youtube.com/watch?v=AO33Yv0RTVs Find out more about the experts Prof. David Hong and Dr Tracy L Stockley The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer and is developed by cor2ed.com.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related